多囊卵巢综合征、复方口服避孕药与血糖异常风险:基于人群的队列研究与巢式药物流行病学病例对照研究
基于英国THIN初级保健数据库的回顾性队列研究(64,051例PCOS女性与123,545例匹配对照)显示,PCOS女性血糖异常调整风险比为1.87(95%CI 1.78-1.97,P<0.001),且所有BMI亚组均升高。巢式病例对照研究(2,407例PCOS女性)发现,使用复方口服避孕药与血糖异常风险降低相关(aOR 0.72,95%CI 0.59-0.87)。
要点
- PCOS女性血糖异常风险显著升高,调整后HR为1.87,各BMI亚组均一致。
- PCOS女性使用COCP与血糖异常风险降低相关,aOR为0.72。
- 研究为回顾性设计,不能排除处方适应证偏倚,需前瞻性研究验证。
核心结论
- PCOS女性血糖异常风险升高,使用COCP与血糖异常风险降低相关,且见于所有BMI亚组。
研究设计与样本
- 巢式药物流行病学病例对照研究:2,407例PCOS女性中比较随访期间发生与未发生血糖异常者的COCP使用。
- 采用Cox模型估计风险比,条件logistic回归估计调整比值比。
主要发现
- PCOS女性血糖异常调整HR为1.87(95%CI 1.78-1.97,P<0.001),调整年龄、社会剥夺、BMI、种族和吸烟。
- 所有BMI亚组中PCOS女性血糖异常发生率均升高。
- PCOS女性使用COCP者血糖异常风险降低,aOR为0.72(95%CI 0.59-0.87)。
临床怎么用
- 对PCOS女性应关注血糖异常筛查,尤其在所有BMI亚组中均需警惕。
- COCP使用与血糖异常风险降低的关联可作参考,但需考虑适应证偏倚,不能直接推断因果。
局限性
- 回顾性研究设计。
- 使用常规收集的电子全科医疗记录数据。
- 无法排除处方适应证偏倚的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Irregular menstrual cycles are associated with increased cardiovascular mortality. Polycystic ovary syndrome (PCOS) is characterized by androgen excess and irregular menses; androgens are drivers of increased metabolic risk in women with PCOS. Combined oral contraceptive pills (COCPs) are used in PCOS both for cycle regulation and to reduce the biologically active androgen fraction. We examined COCP use and risk of dysglycemia (prediabetes and type 2 diabetes) in women with PCOS. RESEARCH DESIGN AND METHODS: Using a large U.K. primary care database (The Health Improvement Network [THIN]; 3.7 million patients from 787 practices), we carried out a retrospective population-based cohort study to determine dysglycemia risk (64,051 women with PCOS and 123,545 matched control subjects), as well as a nested pharmacoepidemiological case-control study to investigate COCP use in relation to dysglycemia risk (2,407 women with PCOS with [case subjects] and without [control subjects] a diagnosis of dysglycemia during follow-up). Cox models were used to estimate the unadjusted and adjusted hazard ratio, and conditional logistic regression was used to obtain adjusted odds ratios (aORs). RESULTS: The adjusted hazard ratio for dysglycemia in women with PCOS was 1.87 (95% CI 1.78-1.97, P < 0.001; adjustment for age, social deprivation, BMI, ethnicity, and smoking), with increased rates of dysglycemia in all BMI subgroups. Women with PCOS and COCP use had a reduced dysglycemia risk (aOR 0.72, 95% CI 0.59-0.87). CONCLUSIONS: In this study, limited by its retrospective nature and the use of routinely collected electronic general practice record data, which does not allow for exclusion of the impact of prescription-by-indication bias, women with PCOS exposed to COCPs had a reduced risk of dysglycemia across all BMI subgroups. Future prospective studies should be considered for further understanding of these observations and potential causality.
引用
- Kumarendran B, O'Reilly MW, Subramanian A, et al. Polycystic Ovary Syndrome, Combined Oral Contraceptives, and the Risk of Dysglycemia: A Population-Based Cohort Study With a Nested Pharmacoepidemiological Case-Control Study. Diabetes Care. 2021. PMID: 34649997. doi:10.2337/dc21-0437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。